Online inquiry

IVTScrip™ mRNA-Anti-APP, R1450(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13605MR)

This product GTTS-WQ13605MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, R1450(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ13605MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4264MR IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BIIB-033
GTTS-WQ8628MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA HuMax-AXL-ADC
GTTS-WQ15793MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ7407MR IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GA201
GTTS-WQ10908MR IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MABT5102A
GTTS-WQ227MR IVTScrip™ mRNA-Anti-B4GALNT1, 14.18 mAb(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 14.18 mAb
GTTS-WQ1088MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-838
GTTS-WQ14034MR IVTScrip™ mRNA-Anti-LAG3, aLAG367(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA aLAG367
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW